{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:51Z","timestamp":1756902171513,"version":"3.44.0"},"reference-count":84,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Cannabis is a highly discussed topic in medicine today. From therapeutic applications in conditions such as chronic pain, multiple sclerosis, epilepsy, chemotherapy-induced nausea and vomiting, and inflammatory bowel disease to the growing prevalence of recreational use, cannabis remains at the forefront of medical and societal conversations. In this review, we will explore the history of marijuana use in medicine, examine the current evidence supporting its pharmacological benefits, and delve into its impact on the developing brain. Additionally, we will highlight the pivotal role pharmacists play in this evolving landscape and guide you through the latest research findings.<\/jats:p>","DOI":"10.5863\/jppt-25-01209","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T19:46:03Z","timestamp":1755114363000},"page":"440-449","source":"Crossref","is-referenced-by-count":0,"title":["Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds"],"prefix":"10.5863","volume":"30","author":[{"given":"Marry","family":"Vuong","sequence":"first","affiliation":[{"name":"Clinical\/Administrative, MV, Perfecting Peds LLC, Miami, FL (MV)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylee","family":"Parkhill","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy (KP), Rutgers, The State University of New Jersey, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"year":"2024","series-title":"Schedules of controlled substances: rescheduling of marijuana. Federal Register","key":"i2331-348X-30-4-440-b01","unstructured":"Schedules of controlled substances: rescheduling of marijuana. Federal Register. May 21, 2024."},{"key":"i2331-348X-30-4-440-b02","series-title":"Epilepsy Behav","first-page":"240","article-title":"Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center","volume":"80","author":"Porcari","year":"2018","unstructured":"Porcari GS, Fu C, Doll ED, et al. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240\u2013246."},{"issue":"4","key":"i2331-348X-30-4-440-b03","series-title":"J Pediatr Adolesc Gynecol","first-page":"349","article-title":"What every pediatric gynecologist should know about marijuana use in adolescents","volume":"32","author":"Chadi","year":"2019","unstructured":"Chadi N, Levy S. What every pediatric gynecologist should know about marijuana use in adolescents. J Pediatr Adolesc Gynecol. 2019;32(4):349\u2013353."},{"issue":"6","key":"i2331-348X-30-4-440-b04","series-title":"J Pediatr Health Care","first-page":"626","article-title":"Medical marijuana in the pediatric population with epilepsy\u2014what you should know","volume":"33","author":"Markle","year":"2019","unstructured":"Markle M, Nativio DG. Medical marijuana in the pediatric population with epilepsy\u2014what you should know. J Pediatr Health Care. 2019;33(6):626\u2013632."},{"issue":"3","key":"i2331-348X-30-4-440-b05","series-title":"J Pediatr Pharmacol Ther","first-page":"176","article-title":"Cannabinoids in pediatrics","volume":"22","author":"Campbell","year":"2017","unstructured":"Campbell CT, Phillips MS, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Ther. 2017;22(3):176\u2013185."},{"issue":"6","key":"i2331-348X-30-4-440-b06","series-title":"Curr Treat Options Gastroenterol","first-page":"519","article-title":"Cannabis in gastroenterology: watch your head! A review of use in inflammatory bowel disease, functional gut disorders, and gut-related adverse effects","volume":"18","author":"Nasser","year":"2020","unstructured":"Nasser Y, Woo M, Andrews CN. Cannabis in gastroenterology: watch your head! A review of use in inflammatory bowel disease, functional gut disorders, and gut-related adverse effects. Curr Treat Options Gastroenterol. 2020;18(6):519\u2013530."},{"issue":"17","key":"i2331-348X-30-4-440-b07","series-title":"J Med Chem","first-page":"14697","article-title":"It\u2019s not \u201cjust weed\u201d anymore","volume":"67","author":"Gilliland","year":"2024","unstructured":"Gilliland K. It\u2019s not \u201cjust weed\u201d anymore. J Med Chem. 2024;67(17):14697\u201314699."},{"year":"2024","series-title":"National Conference of State Legislatures","key":"i2331-348X-30-4-440-b08","unstructured":"Cannabis overview. National Conference of State Legislatures. June 20, 2024."},{"key":"i2331-348X-30-4-440-b09","unstructured":"National Center for Complementary and Integrative Health (NCCIH). Cannabis (marijuana) and cannabinoids: what you need to know. Accessed November 30, 2024. https:\/\/www.nccih.nih.gov\/health\/cannabis-marijuana-and-cannabinoids-what-you-need-to-know","article-title":"Cannabis (marijuana) and cannabinoids: what you need to know"},{"issue":"2","key":"i2331-348X-30-4-440-b10","series-title":"Pediatr Blood Cancer","first-page":"e26826","article-title":"Medical marijuana in pediatric oncology: a review of the evidence and implications for practice","volume":"65","author":"Ananth","year":"2018","unstructured":"Ananth P, Reed-Weston A, Wolfe J. Medical marijuana in pediatric oncology: a review of the evidence and implications for practice. Pediatr Blood Cancer. 2018;65(2):e26826."},{"issue":"10","key":"i2331-348X-30-4-440-b11","series-title":"Pain","first-page":"2215","article-title":"The prevalence of chronic pain in children and adolescents: a systematic review update and meta-analysis","volume":"165","author":"Chambers","year":"2024","unstructured":"Chambers CT, Dol J, Tutelman PR, et al. The prevalence of chronic pain in children and adolescents: a systematic review update and meta-analysis. Pain. 2024;165(10):2215\u20132234."},{"issue":"4","key":"i2331-348X-30-4-440-b12","series-title":"Eur J Pain","first-page":"761","article-title":"Prevalence and associated psychosocial and health factors of chronic pain in adolescents: differences by sex and age","volume":"24","author":"Wager","year":"2020","unstructured":"Wager J, Brown D, Kupitz A, et al. Prevalence and associated psychosocial and health factors of chronic pain in adolescents: differences by sex and age. Eur J Pain. 2020;24(4):761\u2013772."},{"issue":"1","key":"i2331-348X-30-4-440-b13","series-title":"Pain","first-page":"2):132","article-title":"Disability in adolescents with chronic pain: patterns and predictors across different domains of functioning","volume":"131","author":"Gauntlett-Gilbert","year":"2007","unstructured":"Gauntlett-Gilbert J, Eccleston C. Disability in adolescents with chronic pain: patterns and predictors across different domains of functioning. Pain. 2007;131(1\u20132):132\u2013141."},{"issue":"11","key":"i2331-348X-30-4-440-b14","series-title":"JAMA","first-page":"1031","article-title":"New WHO guideline for treating chronic pain in children","volume":"325","author":"Kuehn","year":"2021","unstructured":"Kuehn BM. New WHO guideline for treating chronic pain in children. JAMA. 2021;325(11):1031."},{"issue":"3","key":"i2331-348X-30-4-440-b15","series-title":"Pediatrics","first-page":"584","article-title":"The impact of marijuana policies on youth: clinical, research, and legal update","volume":"135","author":"Ammerman","year":"2015","unstructured":"Ammerman SD, Ryan SA, Adelman WP, et al; Committee on Substance Abuse, Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135(3):584\u2013587."},{"issue":"2","key":"i2331-348X-30-4-440-b16","series-title":"Pain Ther","first-page":"355","article-title":"Cannabinoids as a potential alternative to opioids in the management of various pain subtypes: benefits, limitations, and risks","volume":"12","author":"Ang","year":"2023","unstructured":"Ang SP, Sidharthan S, Lai W, et al. Cannabinoids as a potential alternative to opioids in the management of various pain subtypes: benefits, limitations, and risks. Pain Ther. 2023;12(2):355\u2013375."},{"issue":"4","key":"i2331-348X-30-4-440-b17","series-title":"J Pain Symptom Manage","first-page":"e361","article-title":"Experience with medical marijuana in a pediatric palliative care clinic: case report","volume":"67","author":"Sahli","year":"2021","unstructured":"Sahli J, Grossoehme D, Friebert S. Experience with medical marijuana in a pediatric palliative care clinic: case report. J Pain Symptom Manage. 2021;67(4):e361\u2013e365."},{"article-title":"National Survey of Children\u2019s Health","year":"2022","key":"i2331-348X-30-4-440-b18","unstructured":"Data Research Center. 2022 National Survey of Children\u2019s Health. Accessed February 2, 2024. https:\/\/www.childhealthdata.org\/browse\/survey\/results?q=10071&r=1"},{"issue":"S1","key":"i2331-348X-30-4-440-b19","series-title":"Epileptic Disord","first-page":"10","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","unstructured":"Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10\u201315."},{"key":"i2331-348X-30-4-440-b20","unstructured":"US Food and Drug Administration (FDA). Drug trials snapshots: Epidiolex. Updated November 6, 2023. Accessed November 17, 2024. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-epidiolex","article-title":"Drug trials snapshots: Epidiolex"},{"issue":"21","key":"i2331-348X-30-4-440-b21","series-title":"N Engl J Med","first-page":"2011","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u20132020."},{"issue":"19","key":"i2331-348X-30-4-440-b22","series-title":"N Engl J Med","first-page":"1888","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. N Engl J Med. 2018;378(19):1888\u20131897."},{"issue":"10125","key":"i2331-348X-30-4-440-b23","series-title":"Lancet","first-page":"1085","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u20131096."},{"issue":"3","key":"i2331-348X-30-4-440-b24","series-title":"JAMA Neurol","first-page":"285","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","unstructured":"Thiele EA, Bebin EM, Bhathal H, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78(3):285\u2013292."},{"issue":"5","key":"i2331-348X-30-4-440-b25","series-title":"Epilepsia Open","first-page":"1632","article-title":"Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex","volume":"9","author":"Wechsler","year":"2024","unstructured":"Wechsler RT, Burdette DE, Gidal BE, et al. Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Epilepsia Open. 2024;9(5):1632\u20131642."},{"key":"i2331-348X-30-4-440-b26","series-title":"Mult Scler Relat Disord","first-page":"102260","article-title":"Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis","volume":"44","author":"Yan","year":"2020","unstructured":"Yan K, Balijepalli C, Desai K, et al. Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis. Mult Scler Relat Disord. 2020;44:102260."},{"issue":"5","key":"i2331-348X-30-4-440-b27","series-title":"Pediatrics","first-page":"e20171818","article-title":"Medical cannabinoids in children and adolescents: a systematic review","volume":"140","author":"Wong","year":"2017","unstructured":"Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017;140(5):e20171818."},{"issue":"2","key":"i2331-348X-30-4-440-b28","series-title":"Pharmaceutics","first-page":"241","article-title":"Unveiling the potential of cannabinoids in multiple sclerosis and the dawn of nano-cannabinoid medicine","volume":"16","author":"Nouh","year":"2024","unstructured":"Nouh RA, Kamal A, Oyewole O, et al. Unveiling the potential of cannabinoids in multiple sclerosis and the dawn of nano-cannabinoid medicine. Pharmaceutics. 2024;16(2):241."},{"issue":"4","key":"i2331-348X-30-4-440-b29","series-title":"Pharmaceutics","first-page":"1151","article-title":"Cannabinoids and multiple sclerosis: a critical analysis of therapeutic potentials and safety concerns","volume":"15","author":"Nouh","year":"2023","unstructured":"Nouh RA, Kamal A, Abdelnaser A. Cannabinoids and multiple sclerosis: a critical analysis of therapeutic potentials and safety concerns. Pharmaceutics. 2023;15(4):1151."},{"key":"i2331-348X-30-4-440-b30","series-title":"Neurology","first-page":"1083","article-title":"Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Yadav","year":"2014","unstructured":"Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1083\u20131092."},{"key":"i2331-348X-30-4-440-b31","series-title":"Neurology","first-page":"1556","article-title":"Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Koppel","year":"2014","unstructured":"Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556\u20131563."},{"key":"i2331-348X-30-4-440-b32","series-title":"Neuroimage Clin","first-page":"140","article-title":"Multiple sclerosis, cannabis, and cognition: a structural MRI study","volume":"8","author":"Romero","year":"2015","unstructured":"Romero K, Pavisian B, Staines WR, Feinstein A. Multiple sclerosis, cannabis, and cognition: a structural MRI study. Neuroimage Clin. 2015;8:140\u2013147."},{"issue":"2","key":"i2331-348X-30-4-440-b33","series-title":"J Neurol","first-page":"417","article-title":"Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis","volume":"265","author":"Brenton","year":"2018","unstructured":"Brenton JN, Schreiner T, Karoscik K, et al. Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis. J Neurol. 2018;265(2):417\u2013423."},{"issue":"3","key":"i2331-348X-30-4-440-b34","series-title":"Pediatr Hematol Oncol J","first-page":"171","article-title":"Assessment of chemotherapy-induced nausea and vomiting in pediatrics: adequacy of control and adherence to guidelines","volume":"8","author":"Awwad","year":"2023","unstructured":"Awwad S, Ali A, Alshaikh F, et al. Assessment of chemotherapy-induced nausea and vomiting in pediatrics: adequacy of control and adherence to guidelines. Pediatr Hematol Oncol J. 2023;8(3):171\u2013178."},{"key":"i2331-348X-30-4-440-b35","series-title":"Gut","first-page":"859","article-title":"Cannabinoids and the gastrointestinal tract","volume":"48","author":"Pertwee","year":"2001","unstructured":"Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut. 2001;48:859\u2013867."},{"key":"i2331-348X-30-4-440-b36","series-title":"Synapse","first-page":"470","article-title":"Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain","volume":"1","author":"Blier","year":"1987","unstructured":"Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1987;1:470\u2013480."},{"key":"i2331-348X-30-4-440-b37","series-title":"J Pharmacol Exp Ther","first-page":"547","article-title":"The nonpsychoactive cannabinoid cannabidiol inhibits 5-Hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes","volume":"333","author":"Yang","year":"2010","unstructured":"Yang KH, Galadari S, Isaev D, et al. The nonpsychoactive cannabinoid cannabidiol inhibits 5-Hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther. 2010;333:547\u2013554."},{"key":"i2331-348X-30-4-440-b38","series-title":"J Clin Oncol","first-page":"2782","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782\u20132797."},{"issue":"6","key":"i2331-348X-30-4-440-b39","series-title":"J Pediatr Pharmacol Ther","first-page":"462","article-title":"Characterization of dronabinol usage in a pediatric oncology population","volume":"20","author":"Elder","year":"2015","unstructured":"Elder JJ, Knoderer HM. Characterization of dronabinol usage in a pediatric oncology population. J Pediatr Pharmacol Ther. 2015;20(6):462\u2013467."},{"issue":"4","key":"i2331-348X-30-4-440-b40","series-title":"Inflamm Bowel Dis","first-page":"619","article-title":"Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007\u20132016","volume":"26","author":"Ye","year":"2020","unstructured":"Ye Y, Manne S, Treem WR, Bennett D. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007\u20132016. Inflamm Bowel Dis. 2020;26(4):619\u2013625."},{"issue":"10","key":"i2331-348X-30-4-440-b41","series-title":"Trends Mol Med","first-page":"615","article-title":"The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity","volume":"18","author":"Alhouayek","year":"2012","unstructured":"Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med. 2012;18(10):615\u2013625."},{"issue":"10","key":"i2331-348X-30-4-440-b42","series-title":"Curr Dev Nutr","first-page":"101972","article-title":"Cannabidiol and intestinal motility: a systematic review","volume":"7","author":"Briere","year":"2023","unstructured":"Briere C-E, McClements DJ, Sela DA. Cannabidiol and intestinal motility: a systematic review. Curr Dev Nutr. 2023;7(10):101972."},{"issue":"2","key":"i2331-348X-30-4-440-b43","series-title":"Crohns Colitis 360","first-page":"otaa016","article-title":"Marijuana use in inflammatory bowel disease: understanding the prevalence and the potential pitfalls","volume":"2","author":"Scott","year":"2020","unstructured":"Scott FI. Marijuana use in inflammatory bowel disease: understanding the prevalence and the potential pitfalls. Crohns Colitis 360. 2020;2(2):otaa016."},{"issue":"2","key":"i2331-348X-30-4-440-b44","series-title":"J Pediatr Gastroenterol Nutr","first-page":"265","article-title":"Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high","volume":"64","author":"Hoffenberg","year":"2017","unstructured":"Hoffenberg EJ, Newman H, Collins C, et al. Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high. J Pediatr Gastroenterol Nutr. 2017;64(2):265\u2013271."},{"issue":"10S","key":"i2331-348X-30-4-440-b45","series-title":"Am J Gastroenterol","article-title":"S906: Survey on medical marijuana use in IBD patients in Oklahoma before and after legalization","volume":"117","author":"Nadeem","year":"2022","unstructured":"Nadeem M, Fernandez A, Idrisov E, et al. S906: Survey on medical marijuana use in IBD patients in Oklahoma before and after legalization. Am J Gastroenterol. 2022;117(10S)."},{"issue":"10","key":"i2331-348X-30-4-440-b46","series-title":"Dig Dis Sci","first-page":"2939","article-title":"Association between cannabis use and complications related to Crohn\u2019s disease: a retrospective cohort study","volume":"64","author":"Mbachi","year":"2019","unstructured":"Mbachi C, Attar B, Wang Y, et al. Association between cannabis use and complications related to Crohn\u2019s disease: a retrospective cohort study. Dig Dis Sci. 2019;64(10):2939\u20132944."},{"issue":"2","key":"i2331-348X-30-4-440-b47","series-title":"Am J Obstet Gynecol","first-page":"201.e1","article-title":"Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age","volume":"213","author":"Ko","year":"2015","unstructured":"Ko JY, Farr SL, Tong VT, et al. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol. 2015;213(2):201.e1\u2013201.e10."},{"key":"i2331-348X-30-4-440-b48","series-title":"Obstet Gynecol","first-page":"e205\u20139","article-title":"Marijuana use during pregnancy and lactation. Committee Opinion No. 722. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","unstructured":"Marijuana use during pregnancy and lactation. Committee Opinion No. 722. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e205\u20139."},{"issue":"4","key":"i2331-348X-30-4-440-b49","series-title":"Obstet Gynecol","first-page":"e205","article-title":"Committee Opinion No. 722: marijuana use during pregnancy and lactation","volume":"130","year":"2017","unstructured":"Committee Opinion No. 722: marijuana use during pregnancy and lactation. Obstet Gynecol. 2017;130(4):e205\u2013e209."},{"key":"i2331-348X-30-4-440-b50","series-title":"Marijuana and Madness","first-page":"267","article-title":"Pre-natal cannabis exposure: associations with development and behaviour","author":"Paul","year":"2023","unstructured":"Paul SE, Rogers CE, Bogdan R. Pre-natal cannabis exposure: associations with development and behaviour. In: D\u2019Souza DC, Castle DJ, Murray RM, eds. Marijuana and Madness. 3rd ed. Cambridge University Press; 2023:267\u2013278."},{"issue":"6","key":"i2331-348X-30-4-440-b51","series-title":"Reproduction","first-page":"R191","article-title":"Endocannabinoid system and pregnancy","volume":"152","author":"Correa","year":"2016","unstructured":"Correa F, Wolfson ML, Valchi P, et al. Endocannabinoid system and pregnancy. Reproduction. 2016;152(6):R191\u2013R200."},{"issue":"4","key":"i2331-348X-30-4-440-b52","series-title":"Am J Obstet Gynecol","first-page":"571","article-title":"Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes","volume":"227","author":"Lo","year":"2022","unstructured":"Lo JO, Hedges JC, Girardi G. Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes. Am J Obstet Gynecol. 2022;227(4):571\u2013581."},{"key":"i2331-348X-30-4-440-b53","series-title":"Psychopharmacology (Berl)","first-page":"5","article-title":"Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents","volume":"214","author":"Campolongo","year":"2011","unstructured":"Campolongo P, Trezza V, Ratano P, et al. Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents. Psychopharmacology (Berl). 2011;214:5\u201315."},{"key":"i2331-348X-30-4-440-b54","series-title":"Neuropsychopharmacology","first-page":"1315","article-title":"Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation","volume":"39","author":"Szutorisz","year":"2014","unstructured":"Szutorisz H, DiNieri JA, Sweet E, et al. Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology. 2014;39:1315\u20131323."},{"key":"i2331-348X-30-4-440-b55","series-title":"Ann Neurol","first-page":"42","article-title":"Cannabinoids enhance susceptibility of immature brain to ethanol neurotoxicity","volume":"64","author":"Hansen","year":"2008","unstructured":"Hansen HH, Krutz B, Sifringer M, et al. Cannabinoids enhance susceptibility of immature brain to ethanol neurotoxicity. Ann Neurol. 2008;64:42\u201352."},{"key":"i2331-348X-30-4-440-b56","series-title":"Neurotoxicol Teratol","first-page":"580","article-title":"Effects of prenatal tobacco, alcohol and marijuana exposure on processing speed, visual-motor coordination, and interhemispheric transfer","volume":"32","author":"Willford","year":"2010","unstructured":"Willford JA, Chandler LS, Goldschmidt L, Day NL. Effects of prenatal tobacco, alcohol and marijuana exposure on processing speed, visual-motor coordination, and interhemispheric transfer. Neurotoxicol Teratol. 2010;32:580\u2013588."},{"key":"i2331-348X-30-4-440-b57","series-title":"Alcohol Clin Exp Res","first-page":"455","article-title":"Prenatal exposure to alcohol and marijuana: effects on motor development of preschool children","volume":"20","author":"Chandler","year":"1996","unstructured":"Chandler LS, Richardson GA, Gallagher JD, Day NL. Prenatal exposure to alcohol and marijuana: effects on motor development of preschool children. Alcohol Clin Exp Res. 1996;20:455\u2013461."},{"key":"i2331-348X-30-4-440-b58","series-title":"Neurotoxicol Teratol","first-page":"421","article-title":"Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana","volume":"23","author":"Fried","year":"2001","unstructured":"Fried PA, Watkinson B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol. 2001;23:421\u2013430."},{"key":"i2331-348X-30-4-440-b59","series-title":"Neurotoxicol Teratol","first-page":"325","article-title":"Effects of prenatal marijuana exposure on child behavior problems at age 10","volume":"22","author":"Goldschmidt","year":"2000","unstructured":"Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22:325\u2013336."},{"key":"i2331-348X-30-4-440-b60","series-title":"Obstet Gynecol","first-page":"713","article-title":"Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis","volume":"128","author":"Conner","year":"2016","unstructured":"Conner SN, Bedell V, Lipsey K, et al. Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis. Obstet Gynecol. 2016;128:713\u2013723."},{"issue":"9","key":"i2331-348X-30-4-440-b61","series-title":"JAMA Intern Med","first-page":"1083","article-title":"Prenatal cannabis use and maternal pregnancy outcomes","volume":"184","author":"Young-Wolff","year":"2024","unstructured":"Young-Wolff KC, Adams SR, Alexeeff SE, et al. Prenatal cannabis use and maternal pregnancy outcomes. JAMA Intern Med. 2024;184(9):1083\u20131093."},{"key":"i2331-348X-30-4-440-b62","series-title":"Perm J","first-page":"1","article-title":"Mechanisms of action and pharmacokinetics of cannabis","volume":"25","author":"Chayasirisobhon","year":"2020","unstructured":"Chayasirisobhon S. Mechanisms of action and pharmacokinetics of cannabis. Perm J. 2020;25:1\u20133."},{"issue":"6","key":"i2331-348X-30-4-440-b63","series-title":"JAMA Pediatr","first-page":"632","article-title":"Persistence of \u0394-9-Tetrahydrocannabinol in human breast milk","volume":"175","author":"Wymore","year":"2021","unstructured":"Wymore EM, Palmer C, Wang GS, et al. Persistence of \u0394-9-Tetrahydrocannabinol in human breast milk. JAMA Pediatr. 2021;175(6):632\u2013634."},{"year":"2006","key":"i2331-348X-30-4-440-b64","unstructured":"Drugs and lactation database (LactMed\u00ae) [Internet]. Bethesda, MD: National Institute of Child Health and Human Development; 2006-. Cannabis. Updated September 15, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501587\/"},{"issue":"1","key":"i2331-348X-30-4-440-b65","series-title":"JAMA Netw Open","first-page":"e2145653","article-title":"Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis","volume":"5","author":"Marchand","year":"2022","unstructured":"Marchand G, Masoud AT, Govindan M, et al. Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(1):e2145653."},{"key":"i2331-348X-30-4-440-b66","series-title":"J Dev Behav Pediatr","first-page":"49","article-title":"36-and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol","volume":"11","author":"Fried","year":"1990","unstructured":"Fried PA, Watkinson B. 36-and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr. 1990;11:49\u201358."},{"key":"i2331-348X-30-4-440-b67","series-title":"J Dev Behav Pediatr","first-page":"383","article-title":"60-and 72-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: cognitive and language assessment","volume":"13","author":"Fried","year":"1992","unstructured":"Fried PA, O\u2019Connell CM, Watkinson B. 60-and 72-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: cognitive and language assessment. J Dev Behav Pediatr. 1992;13:383\u2013391."},{"key":"i2331-348X-30-4-440-b68","series-title":"Front Hum Neurosci","first-page":"601","article-title":"Functional connectivity disruption in neonates with prenatal marijuana exposure","volume":"9","author":"Grewen","year":"2015","unstructured":"Grewen K, Salzwedel AP, Gao W. Functional connectivity disruption in neonates with prenatal marijuana exposure. Front Hum Neurosci. 2015;9:601."},{"issue":"1","key":"i2331-348X-30-4-440-b69","series-title":"JAMA Psychiatry","first-page":"64","article-title":"Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD Study","volume":"78","author":"Paul","year":"2021","unstructured":"Paul SE, Hatoum AS, Fine JD, et al. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD Study. JAMA Psychiatry. 2021;78(1):64\u201376."},{"key":"i2331-348X-30-4-440-b70","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"254","article-title":"Prenatal marijuana exposure and intelligence test performance at age 6","volume":"47","author":"Goldschmidt","year":"2008","unstructured":"Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry. 2008;47:254\u2013263."},{"year":"2014","series-title":"Results from the 2013 National Survey on Drug Use and Health: summary of national findings","key":"i2331-348X-30-4-440-b71","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Substance Abuse and Mental Health Services Administration; 2014."},{"key":"i2331-348X-30-4-440-b72","unstructured":"National Institute on Drug Abuse. Marijuana 2018. Cited November 28, 2018. https:\/\/nida.nih.gov\/research-topics\/cannabis-marijuana","article-title":"Marijuana 2018"},{"key":"i2331-348X-30-4-440-b73","article-title":"Monitoring the Future National Survey Results on Drug Use, 1975\u20132017: overview, key findings on adolescent drug use","author":"Johnston","year":"2017","unstructured":"Johnston LD, O\u2019Malley PM, Miech RA, et al. Monitoring the Future National Survey Results on Drug Use, 1975\u20132017: overview, key findings on adolescent drug use. 2017. https:\/\/deepblue.lib.umich.edu\/bitstream\/handle\/2027.42\/142406\/Overview%202017%20FINAL.pdf?sequence=1&isAllowed=y"},{"key":"i2331-348X-30-4-440-b74","unstructured":"Centers for Disease Control and Prevention (CDC). Cannabis and teens. Accessed November 30, 2024. https:\/\/www.cdc.gov\/cannabis\/health-effects\/cannabis-and-teens.html","article-title":"Cannabis and teens"},{"key":"i2331-348X-30-4-440-b75","series-title":"Drug Alcohol Depend","first-page":"181","article-title":"Trends in cannabis use disorders among racial\/ethnic population groups in the United States","volume":"165","author":"Wu","year":"2016","unstructured":"Wu LT, Zhu H, Swartz MS. Trends in cannabis use disorders among racial\/ethnic population groups in the United States. Drug Alcohol Depend. 2016;165:181\u2013190."},{"key":"i2331-348X-30-4-440-b76","unstructured":"Centers for Disease Control and Prevention (CDC). Cannabis and brain health. Accessed November 30, 2024. https:\/\/www.cdc.gov\/cannabis\/health-effects\/brain-health.html","article-title":"Cannabis and brain health"},{"issue":"2","key":"i2331-348X-30-4-440-b77","series-title":"Curr Treat Options Psychiatry","first-page":"144","article-title":"Cannabis and the developing adolescent brain","volume":"7","author":"Fischer","year":"2020","unstructured":"Fischer AS, Tapert SF, Lee Louie D, et al. Cannabis and the developing adolescent brain. Curr Treat Options Psychiatry. 2020;7(2):144\u2013161."},{"issue":"3","key":"i2331-348X-30-4-440-b78","series-title":"Addict Behav","first-page":"319","article-title":"Early-onset drug use and risk for drug dependence problems","volume":"34","author":"Chen","year":"2009","unstructured":"Chen CY, Storr CL, Anthony JC. Early-onset drug use and risk for drug dependence problems. Addict Behav. 2009;34(3):319\u2013322."},{"issue":"3","key":"i2331-348X-30-4-440-b79","series-title":"JAMA Psychiatry","first-page":"292","article-title":"Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review","volume":"73","author":"Volkow","year":"2016","unstructured":"Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292\u2013297."},{"issue":"3","key":"i2331-348X-30-4-440-b80","series-title":"Drug Alcohol Rev","first-page":"309","article-title":"The relationship between non-acute adolescent cannabis use and cognition","volume":"26","author":"Harvey","year":"2007","unstructured":"Harvey MA, Sellman JD, Porter RJ, Frampton CM. The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev. 2007;26(3):309\u2013319."},{"key":"i2331-348X-30-4-440-b81","series-title":"Pharmacol Ther","first-page":"1","article-title":"Cannabis and adolescent brain development","volume":"148","author":"Lubman","year":"2015","unstructured":"Lubman DI, Cheetham A, Yucel M. Cannabis and adolescent brain development. Pharmacol Ther. 2015;148:1\u201316."},{"issue":"40","key":"i2331-348X-30-4-440-b82","series-title":"Proc Natl Acad Sci U S A","first-page":"E2657","article-title":"Persistent cannabis users show neuropsychological decline from childhood to midlife","volume":"109","author":"Meier","year":"2012","unstructured":"Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657\u2013E2664."},{"issue":"9","key":"i2331-348X-30-4-440-b83","series-title":"JAMA Psychiatry","first-page":"1","article-title":"Association of cannabis use during adolescence with neurodevelopment","volume":"78","author":"Albaugh","year":"2021","unstructured":"Albaugh MD, Ottino-Gonzalez J, Sidwell A, et al. Association of cannabis use during adolescence with neurodevelopment. JAMA Psychiatry. 2021;78(9):1\u201311."},{"key":"i2331-348X-30-4-440-b84","series-title":"JAMA Psychiatry","article-title":"An opportunity to advance cannabis science-DEA rescheduling","author":"Hill","unstructured":"Hill KP, Puli AV. An opportunity to advance cannabis science-DEA rescheduling. JAMA Psychiatry. Published online ahead of print February 5, 2025."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/4\/article-p440.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/4\/article-p440.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/4\/article-p440.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T19:46:04Z","timestamp":1755114364000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/4\/article-p440.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":84,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/jppt-25-01209","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}